Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Disc Medicine, Inc.GMTX · Entity 2273 | Director | October 04, 2021 | March 09, 2022 |
| Nightstar Therapeutics plcNITE · Entity 156809 | Chief Development Officer | June 07, 2019 | June 07, 2019 |
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Chief Medical Officer | January 03, 2017 | January 06, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Disc Medicine, Inc.
Report date October 04, 2021 · Filed March 09, 2022 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2031-10-03 | Direct | 15,528 |
Reported balance
After 2021-10-04 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2021-10-04 · Grant · Acquired 15,528 · Balance 15,528 F1: This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date.
Nightstar Therapeutics plc
Report date June 07, 2019 · Filed June 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-06-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-06-07 · Disposition to issuer · Disposed 80,479 · Balance 0 F1: The ordinary shares, nominal value GBP 0.01 per share, of Nightstar Therapeutics plc (the "Issuer") may be represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.24 · Expires 2028-01-30 | Direct | 0 |
Reported balance
After 2019-06-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-06-07 · Disposition to issuer · Disposed 37,500 · Balance 0 F3: Represents the payment per share received in exchange for the cancellation of each option of $25.50, less the applicable exercise price. F2: In connection with the acquisition by Tungsten Bidco Limited of the entire issued and to be issued share capital of the Issuer on June 7, 2019 by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006, all stock options were cancelled in exchange for a payment equal to $25.50 with respect to each ordinary share subject to the option award, less the applicable exercise price. F1: The ordinary shares, nominal value GBP 0.01 per share, of Nightstar Therapeutics plc (the "Issuer") may be represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.74 · Expires 2019-01-21 | Direct | 0 |
Reported balance
After 2019-06-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-06-07 · Disposition to issuer · Disposed 97,400 · Balance 0 F3: Represents the payment per share received in exchange for the cancellation of each option of $25.50, less the applicable exercise price. F2: In connection with the acquisition by Tungsten Bidco Limited of the entire issued and to be issued share capital of the Issuer on June 7, 2019 by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006, all stock options were cancelled in exchange for a payment equal to $25.50 with respect to each ordinary share subject to the option award, less the applicable exercise price. F1: The ordinary shares, nominal value GBP 0.01 per share, of Nightstar Therapeutics plc (the "Issuer") may be represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The ordinary shares, nominal value GBP 0.01 per share, of Nightstar Therapeutics plc (the "Issuer") may be represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.
F2: In connection with the acquisition by Tungsten Bidco Limited of the entire issued and to be issued share capital of the Issuer on June 7, 2019 by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006, all stock options were cancelled in exchange for a payment equal to $25.50 with respect to each ordinary share subject to the option award, less the applicable exercise price.
F3: Represents the payment per share received in exchange for the cancellation of each option of $25.50, less the applicable exercise price.
PTC THERAPEUTICS, INC.
Report date January 03, 2017 · Filed January 06, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,000 |
Reported balance
After 2017-01-03 transaction · row 1
1 source rowRow 1 · 2017-01-03 · Grant · Acquired 6,000 · Balance 6,000 F1: Restricted stock awarded to the Reporting Person vests in four equal annual installments over four years, commencing on January 3, 2018. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.23 · Expires 2027-01-02 | Direct | 35,000 |
Reported balance
After 2017-01-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-03 · Grant · Acquired 35,000 · Balance 35,000 F2: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock awarded to the Reporting Person vests in four equal annual installments over four years, commencing on January 3, 2018.
F2: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 04, 2021 Filed Oct 6, 2021 20:15 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 17,245 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0000899243-21-039454 · doc4.xml · derivative · entry 1 Ong Tuyen · CIK 0001673178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,245 Underlying: Common Stock · 17,245 shares Expires 2031-10-03 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date. Read SEC document |
| October 04, 2021 Filed Mar 9, 2022 23:14 UTC Amendment | Disc Medicine, Inc. GMTX · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 15,528 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001209191-22-017669 · doc4a.xml · derivative · entry 1 Ong Tuyen · CIK 0001673178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,528 Underlying: Common Stock · 15,528 shares Expires 2031-10-03 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:21 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001213900-21-015397 · ownership.xml · derivative · entry 1 Ong Tuyen · CIK 0001673178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-03-11 F1 · derivative.exercise_date: This option shall vest and become exercisable in 36 equal monthly installments following the Grant Date, provided that as of each such date the Grantee remains in a business relationship with the Company. Read SEC document |
| February 05, 2021 Filed Apr 7, 2021 20:08 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 58,855 | $0.00 Strike: $12.66 | $0.00 |
DisclosureSEC source: 0001213900-21-020638 · ownership.xml · derivative · entry 1 Ong Tuyen · CIK 0001673178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,855 Underlying: Common Stock · 58,855 shares Expires 2031-02-04 F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 5, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a Service Relationship with the Company. Read SEC document |
| June 07, 2019 Filed Jun 7, 2019 16:38 UTC | Nightstar Therapeutics plc NITE · Entity 156809 | Disposition to issuerStock Option (Right to Buy) · Derivative | 97,400 | $10.76 Strike: $14.74 | $1,048,024.00 |
DisclosureSEC source: 0001209191-19-035572 · doc4.xml · derivative · entry 3 Ong Tuyen · CIK 0001673178 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 97,400 shares Expires 2019-01-21 F3 · price: Represents the payment per share received in exchange for the cancellation of each option of $25.50, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the acquisition by Tungsten Bidco Limited of the entire issued and to be issued share capital of the Issuer on June 7, 2019 by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006, all stock options were cancelled in exchange for a payment equal to $25.50 with respect to each ordinary share subject to the option award, less the applicable exercise price. F1 · derivative.underlying: The ordinary shares, nominal value GBP 0.01 per share, of Nightstar Therapeutics plc (the "Issuer") may be represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. Read SEC document |
| June 07, 2019 Filed Jun 7, 2019 16:38 UTC | Nightstar Therapeutics plc NITE · Entity 156809 | Disposition to issuerStock Option (Right to Buy) · Derivative | 37,500 | $11.26 Strike: $14.24 | $422,250.00 |
DisclosureSEC source: 0001209191-19-035572 · doc4.xml · derivative · entry 2 Ong Tuyen · CIK 0001673178 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 37,500 shares Expires 2028-01-30 F3 · price: Represents the payment per share received in exchange for the cancellation of each option of $25.50, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the acquisition by Tungsten Bidco Limited of the entire issued and to be issued share capital of the Issuer on June 7, 2019 by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006, all stock options were cancelled in exchange for a payment equal to $25.50 with respect to each ordinary share subject to the option award, less the applicable exercise price. F1 · derivative.underlying: The ordinary shares, nominal value GBP 0.01 per share, of Nightstar Therapeutics plc (the "Issuer") may be represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. Read SEC document |
| June 07, 2019 Filed Jun 7, 2019 16:38 UTC | Nightstar Therapeutics plc NITE · Entity 156809 | Disposition to issuerOrdinary Shares | 80,479 | $25.50 | $2,052,214.50 |
DisclosureSEC source: 0001209191-19-035572 · doc4.xml · nonDerivative · entry 1 Ong Tuyen · CIK 0001673178 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The ordinary shares, nominal value GBP 0.01 per share, of Nightstar Therapeutics plc (the "Issuer") may be represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:01 UTC | Nightstar Therapeutics plc NITE · Entity 156809 | SaleOrdinary Shares | 2,446 | $25.31 | $61,908.26 |
DisclosureSEC source: 0001209191-19-023560 · doc4.xml · nonDerivative · entry 1 Ong Tuyen · CIK 0001673178 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,479 F1 · security: The ordinary shares, nominal value GBP 0.01 per share, of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F2 · kind: This transaction was effected by the Reporting Person to cover tax liabilities pursuant to the Issuer's mandatory sell-to-cover policy. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 21:03 UTC | Nightstar Therapeutics plc NITE · Entity 156809 | GrantStock Option (Right to Buy) · Derivative | 97,400 | $0.00 Strike: $14.74 | $0.00 |
DisclosureSEC source: 0001209191-19-005264 · doc4.xml · derivative · entry 1 Ong Tuyen · CIK 0001673178 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,400 Underlying: Ordinary Shares · 97,400 shares Expires 2029-01-21 F1 · derivative.exercise_date: This option will vest as to 25% on January 1, 2020. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. F2 · derivative.underlying: The ordinary shares, nominal value GBP 0.01 per share, of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:12 UTC | Nightstar Therapeutics plc NITE · Entity 156809 | SaleOrdinary Shares | 2,546 | $12.98 | $33,049.12 |
DisclosureSEC source: 0001209191-19-003181 · doc4.xml · nonDerivative · entry 1 Ong Tuyen · CIK 0001673178 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,925 F1 · security: The ordinary shares, nominal value GBP 0.01 per share, of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F2 · kind: This transaction was effected by the Reporting Person to cover tax liabilities pursuant to the Issuer's mandatory sell-to-cover policy. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 21:20 UTC | Nightstar Therapeutics plc NITE · Entity 156809 | SaleOrdinary Shares | 4,070 | $12.00 | $48,840.00 |
DisclosureSEC source: 0001209191-19-002676 · doc4.xml · nonDerivative · entry 1 Ong Tuyen · CIK 0001673178 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,070 F1 · security: The ordinary shares, nominal value GBP 0.01 per share, of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| January 03, 2019 Filed Jan 9, 2019 21:09 UTC Amendment | Nightstar Therapeutics plc NITE · Entity 156809 | SaleOrdinary Shares | 4,070 | $12.00 | $48,840.00 |
DisclosureSEC source: 0001209191-19-003178 · doc4a.xml · nonDerivative · entry 1 Ong Tuyen · CIK 0001673178 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,471 F1 · security: The ordinary shares, nominal value GBP 0.01 per share, of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · balance_after: The original Form 4 has been amended to include all unvested restricted shares disclosed in the Reporting Person's Form 3 in Column 5 of this Form 4/A. This Form 4/A amends and restates, in its entirety, the original Form 4. Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 00:13 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 35,000 | $0.00 Strike: $11.23 | $0.00 |
DisclosureSEC source: 0001070081-17-000025 · wf-form4_148366159127249.xml · derivative · entry 2 Ong Tuyen · CIK 0001673178 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-01-02 F2 · derivative.exercise_date: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 00:13 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001070081-17-000025 · wf-form4_148366159127249.xml · nonDerivative · entry 1 Ong Tuyen · CIK 0001673178 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · shares: Restricted stock awarded to the Reporting Person vests in four equal annual installments over four years, commencing on January 3, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.